|
End-of-day quote
Shanghai S.E.
2026-08-24
|
5-day change | 1st Jan Change | ||
| 6.780 CNY | -1.31% |
|
-2.73% | +4.47% |
| Market Cap | 4.69B 699M 598M 560M 512M 966M 66.92B 978M 6.62B 2.58B 33.53B 2.62B 2.57B 111B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.91B 582M 498M 466M 426M 804M 55.73B 814M 5.52B 2.14B 27.93B 2.19B 2.14B 92.61B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
79.74% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | -1.31% | ||
| 1 week | -2.73% | ||
| Current month | +4.79% | ||
| 1 month | +2.88% | ||
| 3 months | +5.12% | ||
| 6 months | +2.42% | ||
| Current year | +4.47% |
| 1 week | 6.72 |  | 7.25 |
| 1 month | 6.33 | | 7.45 |
| Current year | 5.6 | | 7.45 |
| 1 year | 5.6 | | 7.45 |
| 3 years | 4.94 | | 9 |
| 5 years | 4.94 | | 11.9 |
| 10 years | 4.5 | | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 2019-04-22 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 2017-05-16 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 2007-03-10 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 2005-05-25 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 2014-05-14 |
Wei Ren
BRD | Director/Board Member | 42 | 2019-04-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.31% | -2.73% | -7.25% | -8.87% | 707M | |
| +0.40% | -1.04% | +16.34% | +69.97% | 47.71B | |
| +0.12% | +1.50% | +51.38% | +122.20% | 40.3B | |
| +0.40% | -0.83% | -9.73% | +16.84% | 12.09B | |
| -1.45% | -2.77% | +11.63% | +71.04% | 11.68B | |
| +0.19% | +0.58% | +30.98% | +158.71% | 9.19B | |
| +3.49% | +2.54% | +24.70% | +43.56% | 7.57B | |
| -0.16% | +0.58% | +47.14% | -11.83% | 7.24B | |
| +3.14% | +3.12% | +23.40% | +215.25% | 6.84B | |
| -3.24% | -9.40% | -40.05% | +18.52% | 5.42B | |
| Average | +0.16% | -1.65% | +14.85% | +69.54% | 14.87B | |
| Weighted average by Cap. | +0.28% | -0.67% | +24.33% | +84.48% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 400M 342M 320M 293M 553M 38.31B 560M 3.79B 1.47B 19.2B 1.5B 1.47B 63.66B | 2.24B 334M 286M 267M 244M 461M 31.95B 467M 3.16B 1.23B 16.01B 1.25B 1.23B 53.09B |
| Net income | 243M 36.16M 30.94M 28.95M 26.47M 49.95M 3.46B 50.57M 343M 133M 1.73B 136M 133M 5.75B | 320M 47.68M 40.79M 38.18M 34.9M 65.87M 4.56B 66.68M 452M 176M 2.29B 179M 175M 7.58B |
| Net Debt | -483M -71.95M -61.56M -57.61M -52.66M -99.4M -6.89B -101M -682M -265M -3.45B -270M -264M -11.45B | -784M -117M -99.98M -93.57M -85.54M -161M -11.19B -163M -1.11B -431M -5.61B -439M -429M -18.59B |
Employees
3,415
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-24 | CN¥6.780 | -1.31% | 19,598,659 |
| 26-08-21 | CN¥6.870 | -3.92% | 30,607,954 |
| 26-08-20 | CN¥7.150 | +2.29% | 32,805,500 |
| 26-08-19 | CN¥6.990 | -1.41% | 30,889,027 |
| 26-08-18 | CN¥7.090 | -0.98% | 25,905,100 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
